CL2011002689A1 - Microcapsulas que comprenden una suspension de celulas hepaticas en contacto con eritropoyetina estimulante de celulas hepaticas; metodo para preparar microcapsulas; y uso de las microcapsulas para tratar enfermedad hepatica. - Google Patents

Microcapsulas que comprenden una suspension de celulas hepaticas en contacto con eritropoyetina estimulante de celulas hepaticas; metodo para preparar microcapsulas; y uso de las microcapsulas para tratar enfermedad hepatica.

Info

Publication number: CL2011002689A1
Authority: CL; Chile
Prior art keywords: microcapsules; suspension; contact; cell stimulating; hepatic cell
Prior art date: 2009-04-27

Application number

CL2011002689A

Other languages

English (en)

Inventor

Krasimira Aleksandrova

Peter Pediaditakis

Jo Salisbury

Wolfgang Rudinger

Original Assignee

Cytonet Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-27

Filing date

2011-10-27

Publication date

2012-04-27

2011-10-27 Application filed by Cytonet Gmbh & Co Kg filed Critical Cytonet Gmbh & Co Kg

2012-04-27 Publication of CL2011002689A1 publication Critical patent/CL2011002689A1/es

Links

239000003094 microcapsule Substances 0.000 title 3
102000003951 Erythropoietin Human genes 0.000 title 1
108090000394 Erythropoietin Proteins 0.000 title 1
229940105423 erythropoietin Drugs 0.000 title 1
210000003494 hepatocyte Anatomy 0.000 title 1
210000005229 liver cell Anatomy 0.000 title 1
208000019423 liver disease Diseases 0.000 title 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title 1
230000004936 stimulating effect Effects 0.000 title 1
239000000725 suspension Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Immunology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Inorganic Chemistry (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2011002689A 2009-04-27 2011-10-27 Microcapsulas que comprenden una suspension de celulas hepaticas en contacto con eritropoyetina estimulante de celulas hepaticas; metodo para preparar microcapsulas; y uso de las microcapsulas para tratar enfermedad hepatica. CL2011002689A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US12/430,330 US20100272816A1 (en)	2009-04-27	2009-04-27	Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient

Publications (1)

Publication Number	Publication Date
CL2011002689A1 true CL2011002689A1 (es)	2012-04-27

Family

ID=42790675

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2011002689A CL2011002689A1 (es)	2009-04-27	2011-10-27	Microcapsulas que comprenden una suspension de celulas hepaticas en contacto con eritropoyetina estimulante de celulas hepaticas; metodo para preparar microcapsulas; y uso de las microcapsulas para tratar enfermedad hepatica.

Country Status (25)

Country	Link
US (3)	US20100272816A1 (es)
EP (1)	EP2424510B1 (es)
JP (1)	JP5702771B2 (es)
KR (1)	KR101372384B1 (es)
CN (2)	CN103638002B (es)
AU (1)	AU2010243888C1 (es)
BR (1)	BRPI1014835A8 (es)
CL (1)	CL2011002689A1 (es)
CY (1)	CY1114464T1 (es)
DK (1)	DK2424510T3 (es)
ES (1)	ES2431297T3 (es)
HR (1)	HRP20130963T1 (es)
IL (1)	IL215887A (es)
MX (1)	MX2011010993A (es)
NZ (1)	NZ595511A (es)
PL (1)	PL2424510T3 (es)
PT (1)	PT2424510E (es)
RS (1)	RS52989B (es)
RU (2)	RU2500390C2 (es)
SG (1)	SG175792A1 (es)
SI (1)	SI2424510T1 (es)
SM (1)	SMT201300111B (es)
UA (1)	UA99686C2 (es)
WO (1)	WO2010124837A2 (es)
ZA (1)	ZA201106817B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20170141723A1 (en) *	2014-07-25	2017-05-18	Sekisui Chemical Co., Ltd.	Power generation device provided with secondary battery
US10179896B2 (en)	2015-05-12	2019-01-15	Baker Group, LLP	Method and system for a bioartificial organ
RU2618989C1 (ru) *	2016-03-09	2017-05-11	Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ)	Способ лечения печеночной недостаточности
CN110129253A (zh) *	2016-09-14	2019-08-16	四川蓝光英诺生物科技股份有限公司	人工组织前体及制备其的方法
US11439731B2 (en)	2016-09-14	2022-09-13	Revotek Co., Ltd.	Artificial tissue progenitor and method for preparing the same
WO2018093069A1 (ko) *	2016-11-15	2018-05-24	광주과학기술원	세포 3d 배양 방법
CN113573746A (zh) *	2019-03-20	2021-10-29	公立大学法人横滨市立大学	包覆固定剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5455790A (en)	1977-10-05	1979-05-04	Tomoyuki Tajima	Production of erythropoetin
JPS6045849B2 (ja)	1980-08-25	1985-10-12	林原健	ヒトエリトロポエチンの製造方法
NZ210501A (en)	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4956128A (en) *	1984-05-25	1990-09-11	Connaught Laboratories Limited	Droplet generation
IL77081A (en)	1984-12-04	1999-10-28	Genetics Inst	Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5084350A (en) *	1990-02-16	1992-01-28	The Royal Institution For The Advance Of Learning (Mcgill University)	Method for encapsulating biologically active material including cells
CN1125401A (zh)	1993-04-29	1996-06-26	艾博特公司	促红细胞生成素类似物组合物和方法
IL192290A0 (en)	1993-08-17	2008-12-29	Kirin Amgen Inc	Erythropoietin analogs
US6281015B1 (en)	1994-12-16	2001-08-28	Children's Medical Center Corp.	Localized delivery of factors enhancing survival of transplanted cells
MXPA05000858A (es)	2002-07-19	2005-10-19	Vesta Therapeutics Inc	Metodo de obtener celulas hepaticas humanas viables, incluyendo celulas hepaticas troncales/progenitoras.
DK1699915T3 (da)	2003-12-30	2010-09-13	Augustinus Bader	Anvendelse af erythropoietin til levervævsregenerering
US8580248B2 (en) *	2004-03-30	2013-11-12	Fac8Cell Pty Limited	Culture and use of cells that secrete liver secretory factors
RU2429864C2 (ru)	2005-10-21	2011-09-27	Ливинг Селл Продактс Пти Лимитед	Система инкапсуляции

2009
- 2009-04-27 US US12/430,330 patent/US20100272816A1/en not_active Abandoned
2010
- 2010-04-27 ES ES10721304T patent/ES2431297T3/es active Active
- 2010-04-27 CN CN201310424282.3A patent/CN103638002B/zh not_active Expired - Fee Related
- 2010-04-27 EP EP10721304.3A patent/EP2424510B1/en active Active
- 2010-04-27 RS RS20130454A patent/RS52989B/sr unknown
- 2010-04-27 PL PL10721304T patent/PL2424510T3/pl unknown
- 2010-04-27 RU RU2011148106/15A patent/RU2500390C2/ru active
- 2010-04-27 MX MX2011010993A patent/MX2011010993A/es active IP Right Grant
- 2010-04-27 RU RU2013143436/15A patent/RU2564924C2/ru active
- 2010-04-27 SG SG2011078375A patent/SG175792A1/en unknown
- 2010-04-27 KR KR1020117028010A patent/KR101372384B1/ko not_active Expired - Fee Related
- 2010-04-27 WO PCT/EP2010/002563 patent/WO2010124837A2/en not_active Ceased
- 2010-04-27 SI SI201030374T patent/SI2424510T1/sl unknown
- 2010-04-27 UA UAA201112582A patent/UA99686C2/ru unknown
- 2010-04-27 NZ NZ595511A patent/NZ595511A/xx not_active IP Right Cessation
- 2010-04-27 AU AU2010243888A patent/AU2010243888C1/en not_active Ceased
- 2010-04-27 JP JP2012506407A patent/JP5702771B2/ja not_active Expired - Fee Related
- 2010-04-27 PT PT107213043T patent/PT2424510E/pt unknown
- 2010-04-27 HR HRP20130963AT patent/HRP20130963T1/hr unknown
- 2010-04-27 BR BRPI1014835A patent/BRPI1014835A8/pt not_active Application Discontinuation
- 2010-04-27 US US13/263,352 patent/US8535923B2/en not_active Expired - Fee Related
- 2010-04-27 CN CN2010800188449A patent/CN102413820B/zh not_active Expired - Fee Related
- 2010-04-27 DK DK10721304.3T patent/DK2424510T3/da active
2011
- 2011-09-19 ZA ZA2011/06817A patent/ZA201106817B/en unknown
- 2011-10-24 IL IL215887A patent/IL215887A/en active IP Right Grant
- 2011-10-27 CL CL2011002689A patent/CL2011002689A1/es unknown
2013
- 2013-09-16 US US14/027,932 patent/US9517247B2/en not_active Expired - Fee Related
- 2013-10-04 SM SM201300111T patent/SMT201300111B/xx unknown
- 2013-10-09 CY CY20131100876T patent/CY1114464T1/el unknown

Also Published As

Publication number	Publication date
ES2431297T3 (es)	2013-11-25
KR20120014171A (ko)	2012-02-16
SMT201300111B (it)	2013-11-08
IL215887A0 (en)	2012-01-31
JP5702771B2 (ja)	2015-04-15
SG175792A1 (en)	2011-12-29
UA99686C2 (ru)	2012-09-10
US8535923B2 (en)	2013-09-17
US9517247B2 (en)	2016-12-13
HRP20130963T1 (hr)	2013-11-22
KR101372384B1 (ko)	2014-03-12
CY1114464T1 (el)	2016-10-05
WO2010124837A2 (en)	2010-11-04
RU2013143436A (ru)	2015-03-27
CN103638002A (zh)	2014-03-19
HK1165278A1 (en)	2012-10-05
WO2010124837A3 (en)	2011-02-10
BRPI1014835A8 (pt)	2018-02-14
AU2010243888A1 (en)	2011-10-27
CN102413820B (zh)	2013-09-25
SI2424510T1 (sl)	2013-11-29
MX2011010993A (es)	2011-11-02
US20120093937A1 (en)	2012-04-19
NZ595511A (en)	2013-02-22
PL2424510T3 (pl)	2013-12-31
ZA201106817B (en)	2012-11-28
CN102413820A (zh)	2012-04-11
RU2564924C2 (ru)	2015-10-10
IL215887A (en)	2016-05-31
JP2012524739A (ja)	2012-10-18
US20140017305A1 (en)	2014-01-16
EP2424510A2 (en)	2012-03-07
PT2424510E (pt)	2013-10-14
BRPI1014835A2 (pt)	2016-04-12
CN103638002B (zh)	2016-05-18
RU2011148106A (ru)	2013-06-10
RU2500390C2 (ru)	2013-12-10
RS52989B (sr)	2014-02-28
DK2424510T3 (da)	2013-10-07
US20100272816A1 (en)	2010-10-28
EP2424510B1 (en)	2013-07-17
AU2010243888C1 (en)	2014-01-23
AU2010243888B2 (en)	2013-08-22

Publication	Publication Date	Title
CL2013002029A1 (es)	2014-05-09	Celula progenitora y no diferenciada neural humana expandible aislada; composicion que la comprende; metodo de cultivo in vitro; dicho cultivo in vitro; y su uso para tratar una condicion causada por perdida de mielina o de oligodendrocitos.
CL2013002438A1 (es)	2014-08-29	Metodo para crear modificación genética en una célula de ganado usando acido nucleico que codifica una molecula efectora y nucleasas efectoras (talens)
IL259642B (en)	2021-12-01	Methods for enhancing natural killer cell proliferation and activity
BR112013027187A2 (pt)	2017-06-06	composto que compreende um oligonucleotídeo modificado complementar a mir-21; oligonucleotídeo modificado; composição farmacêutica; método para diminuir a expressão de colágeno em uma célula; e uso de um composto
BRPI0921726A2 (pt)	2016-12-06	método e dispositivo para ativar células tronco
BR112012009921A2 (pt)	2016-03-08	métodos para reprogramar células e usos do mesmos
BRPI1013771A2 (pt)	2016-04-05	"células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores."
PL3144389T3 (pl)	2018-10-31	WYTWARZANIE I STOSOWANIE ZSYNTETYZOWANEGO IN VITRO ssRNA DO WPROWADZANIA DO SSACZYCH KOMÓREK W CELU INDUKCJI EFEKTU BIOLOGICZNEGO LUB BIOCHEMICZNEGO
BRPI0913670A2 (pt)	2016-07-26	célula de levedura para produzir isobutanol e método de produção de isobutanol com células de levedura
BR112012025699A2 (pt)	2017-12-12	estrutura de laminado com cavidades embutidas para uso com células solares e método de fabricação relacionado
BRPI0921467A2 (pt)	2015-08-18	Enzimas e métodos para produzir ácidos graxos ômega-3
BRPI0922355A2 (pt)	2017-10-24	ácidos nucléicos, métodos para reduzir a expressão de um gene em uma célula in vitro, uso de um ácido nucléico, complexo de rna e uso do complexo de rna
PT2752484T (pt)	2018-03-01	Método para preparar um meio de cultura básico para células estaminais mesenquimais, meio de cultura básico para células estaminais mesenquimais, e agente terapêutico celular cultivado e diferenciado usando o mesmo
CL2015003599A1 (es)	2016-12-09	Solucion que contiene theralosa y dextrano para transplantar celulas de mamiferos
IL230212B (en)	2018-08-30	Media, compositions and methods for enhancing bioenergetic status in female germ cells
BRPI0911773A2 (pt)	2019-09-24	eletrodo frontal transparente para uso em dispositivo fotovoltaico e método de produção do mesmo
BRPI0909817A2 (pt)	2017-06-13	uso de células-tronco mesenquimais para tratamento de doenças e distúrbios genéticos
BRPI0913640A2 (pt)	2016-08-16	substâncias policrômicas e seus usos
EP2195853A4 (en)	2012-10-17	SOLAR CELL AND METHOD FOR MANUFACTURING SAME
ATE522136T1 (de)	2011-09-15	Wirkstoffsuspensionen in glycerin
BR112012032172A2 (pt)	2015-11-24	método para produzir um álcool e composição
CL2011002816A1 (es)	2012-06-01	Metodo y aparato para reducir una materia prima solida que comprende disponer dicha materia prima sobre elementos con superficies catodicas de un conjunto de celdas bipolares dentro de un alojamiento, hacer circular sal fundida para que entre en contacto con los elementos y la materia prima y aplicar un potencial electrico.
BR112013001423A2 (pt)	2016-05-24	método, método in vitro, uso e kit útil para realizar o método
PT3272861T (pt)	2020-03-26	Construção de ácido nucleico para expressão de alfα-galactosidase em plantas e células de plantas
FI20135785L (fi)	2013-07-19	Modulaariset anodikokoonpanot ja menetelmiä niiden käyttämiseksi sähkökemiallisessa pelkistyksessä